Argentina Menopause Drugs Market - Industry Trends and Forecast to 2029
- Published Date: 2022-11-22
- Report ID: 144161
- Pages: 200
-
Format:
Short Description:
Argentina Menopause Drugs Market, By Stages (Postmenopause, Perimenopause and Menopause), Type (Non-Hormonal Therapy and Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Dyspareunia, Osteoporosis, Joint Pain, Depression, Weight Gain and Others), Dosage Form (Tablet, Cream, Patch/Film, Rings, Gel, Injection Shot, Spray and Others), Route of Administration (Oral, Parenteral, Transdermal, Vaginal and Others), End User (Hospitals, Clinic Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Argentina) Industry Trends and Forecast to 2029.
Market Definition:
The term menopause means a specific time period, for 12 months after a woman's last period. The years leading up to the point, when women may have changes in the menstrual cycles. During menopause, a woman's body makes less of the hormones estrogen and progesterone. The lower hormone levels, lead to onset of menopause symptoms such as hot flashes, vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression and weight gain.
Some women choose to treat their menopause symptoms with hormonal and non-hormonal therapies. The hormonal therapy medications are estrogen, progesterone, a cocktail of estrogen with progesterone drugs and medroxyprogesterone acetate. The progestin-only medicines are taken with estrogen-only medicines, to lower the chance of getting endometrial cancer in women who still have their uterus.
Argentina has one of the largest populations of the elderly people in Latin America. The ageing population in Argentina are due to rise in fertility and mortality rates. The shift causes an increase in demand for long-term care for older people, particularly those requiring help with activities of daily living.
Market Segmentation:
The Argentina menopause drugs market is categorized into seven segments: stages, type, menopause symptoms, and dosage forms, route of administration, end user and distribution channel.
On the basis of stages, the Argentina menopause drugs market is segmented into postmenopause, perimenopause, and menopause
On the basis of type, the Argentina menopause drugs market is segmented into non-hormonal therapy and hormonal therapy
On the basis of menopause symptoms, the Argentina menopause drugs market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression, weight gain and others
On the basis of dosage form, the Argentina menopause drugs market is segmented into tablet, cream, patch/film, rings, gel, injection shot, spray, and others
On the basis of route of administration, the Argentina menopause drugs market is segmented into oral, parenteral, transdermal, vaginal, and others
On the basis of end user, the Argentina menopause drugs market is segmented into hospitals, clinics, home healthcare, and others
On the basis of distribution channel, the Argentina menopause drugs market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy
Market Players:
The key market players for menopause drugs market are listed below:
Laboratorios Bag S.A.
Qumica Montpellier S.A.
GADOR S.A.
Laboratorio Elea Phoenix S.A.
ROEMMERS SAICF
ACH LABORATRIOS FARMACUTICOS S.A.,
Abbott
Laboratorios Bernab
GlaxoSmithKline plc
TEMIS LOSTALO
Novartis AG
Novo Nordisk A/S
Pfizer Inc.
Allergan
Teva Pharmaceutical Industries Ltd.
Bayer AG
TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF ARGENTINA MENOPAUSE DRUGSMARKET 14
1.4 CURRENCY AND PRICING 16
1.5 LIMITATIONS 17
1.6 MARKETS COVERED 17
2 ARGENTINA MENOPAUSE DRUGSMARKET: SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 COUNTRY SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 DBMR TRIPOD DATA VALIDATION MODEL 22
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.6 MULTIVARIATE MODELLING 26
2.7 CAUSE SEGMENT LIFELINE CURVE 26
2.8 DBMR MARKET POSITION GRID 27
2.9 VENDOR SHARE ANALYSIS 29
2.10 MARKET END USER COVERAGE GRID 30
2.11 SECONDARY SOURCES 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 PORTERS FIVE FORCES 36
4.2 PESTEL ANALYSIS 37
5 EPIDEMIOLOGY 38
6 ARGENTINA MENOPAUSE DRUGS MARKET: REGULATIONS 39
6.1 ARGENTINA 39
6.2 COUNTRY SPECIFIC REQUIREMENTS 40
7 PIPELINE ANALYSIS, ARGENTINA MENOPAUSE DRUGS MARKET 41
8 SUMMARY WRITE UP (ARGENTINA) 42
8.1 OVERVIEW 42
9 MARKET OVERVIEW 43
9.1 DRIVERS 45
9.1.1 RISE IN RESEARCH AND DEVELOPMENT 45
9.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN ARGENTINA 45
9.1.3 RISE IN PRODUCT APPROVAL 46
9.1.4 RISE IN GOVERNMENT INITIATIVES AND ORGANIZATIONS 46
9.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT 47
9.2 RESTRAINTS 47
9.2.1 RISE IN COST OF MENOPAUSE DRUGS AND HORMONAL THERAPY 47
9.2.2 COMPLEXITY IN MENOPAUSE 47
9.2.3 RISE IN PRODUCT RECALL 48
9.2.4 LACK OF AWARENESS ABOUT MENOPAUSE 48
9.3 OPPORTUNITIES 48
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 48
9.3.2 RISE IN HEALTHCARE EXPENDITURE 49
9.3.3 USE OF DIETARY SUPPLEMENTS 49
9.4 CHALLENGES 50
9.4.1 SIDE EFFECTS CAUSED DUE TO DRUGS TAKEN FOR MENOPAUSE TREATMENT 50
9.4.2 STRINGENT REGULATIONS 50
10 IMPACT OF COVID-19 ON ARGENTINA MENOPAUSE DRUGS MARKET 51
10.1 IMPACT ON PRICE 51
10.2 IMPACT ON DEMAND 51
10.3 IMPACT ON SUPPLY CHAIN 52
10.4 STRATEGIC DECISIONS BY MANUFACTURERS 52
10.5 CONCLUSION 53
11 ARGENTINA MENOPAUSE DRUGS MARKET, BY STAGES 54
11.1 OVERVIEW 55
11.2 POSTMENOPAUSE 58
11.3 PERIMENOPAUSE 58
11.4 MENOPAUSE 58
12 ARGENTINA MENOPAUSE DRUGS MARKET, BY TYPE 59
12.1 OVERVIEW 60
12.2 NON-HORMONAL THERAPY 63
12.2.1 MEDICATION 63
12.2.1.1 PAROXETINE 64
12.2.1.2 ANTI-DEPRESSANTS 64
12.2.1.3 GABAPENTIN 64
12.2.1.4 CLONIDINE 64
12.2.1.5 OSPEMIFENE 64
12.2.1.6 OTHERS 64
12.2.2 SUPPLEMENTS 64
12.2.2.1 HERBAL SUPPLEMENTS 65
12.2.2.1.1 GINSENG 65
12.2.2.1.2 ASHWAGANDHA 65
12.2.2.1.3 OTHERS 65
12.2.2.2 VITAMIN D 65
12.2.2.3 OTHERS 65
12.3 HORMONAL THERAPY 66
12.3.1 ESTROGEN 66
12.3.1.1 17 B- ESTRADIOL 67
12.3.1.2 CONJUGATED ESTROGEN 67
12.3.1.3 ESTRADIOL HEMIHYDRATE 67
12.3.1.4 ESTERIFIED ESTROGEN 67
12.3.1.5 ESTERIFIED ACETATE 67
12.3.1.6 ESTROPIPATE 67
12.3.1.7 OTHERS 67
12.3.2 COMBINED ESTROGEN & PROGESTOGEN DRUGS 67
12.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P) 68
12.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P) 68
12.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) 68
12.3.2.4 OTHERS 68
12.3.3 MEDROXYPROGESTERONE ACETATE 68
13 ARGENTINA MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS 69
13.1 OVERVIEW 70
13.2 VASOMOTOR SYMPTOMS 73
13.2.1 HORMONAL THERAPY 73
13.2.2 NON- HORMONAL THERAPY 73
13.3 ATROPHIC VAGINITIS 73
13.3.1 HORMONAL THERAPY 74
13.3.2 NON- HORMONAL THERAPY 74
13.4 DYSPAREUNIA 74
13.4.1 NON- HORMONAL THERAPY 74
13.4.2 HORMONAL THERAPY 74
13.5 OSTEOPOROSIS 74
13.5.1 NON- HORMONAL THERAPY 75
13.5.2 HORMONAL THERAPY 75
13.6 JOINT PAIN 75
13.6.1 NON- HORMONAL THERAPY 76
13.6.2 HORMONAL THERAPY 76
13.7 DEPRESSION 76
13.7.1 NON- HORMONAL THERAPY 77
13.7.2 HORMONAL THERAPY 77
13.8 WEIGHT GAIN 77
13.8.1 HORMONAL THERAPY 78
13.8.2 NON- HORMONAL THERAPY 78
13.9 OTHERS 78
14 ARGENTINA MENOPAUSE DRUGS MARKET, BY DOSAGE FORM 79
14.1 OVERVIEW 80
14.2 TABLET 83
14.3 CREAM 83
14.4 PATCH/FILM 83
14.5 RINGS 83
14.6 GEL 84
14.7 INJECTION SHOT 84
14.8 SPRAY 84
14.9 OTHERS 85
15 ARGENTINA MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION 86
15.1 OVERVIEW 87
15.2 ORAL 90
15.3 PARENTERAL 90
15.3.1 INTRAVENOUS 90
15.3.2 SUBCUTANEOUS 90
15.3.3 OTHERS 91
15.4 TRANSDERMAL 91
15.5 VAGINAL 91
15.6 OTHERS 91
16 ARGENTINA MENOPAUSE DRUGS MARKET, BY END USER 92
16.1 OVERVIEW 93
16.2 HOSPITAL 96
16.3 CLINICS 96
16.4 HOME HEALTHCARE 96
16.5 OTHERS 97
17 ARGENTINA MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL 98
17.1 OVERVIEW 99
17.2 RETAIL PHARMACY 102
17.3 HOSPITAL PHARMACY 102
17.4 ONLINE PHARMACY 102
18 ARGENTINA MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE 103
18.1 COMPANY SHARE ANALYSIS: ARGENTINA 103
19 SWOT ANALYSIS 104
20 COMPANY PROFILE 105
20.1 PFIZER INC. 105
20.1.1 COMPANY SNAPSHOT 105
20.1.2 REVENUE ANALYSIS 105
20.1.3 PRODUCT PORTFOLIO 106
20.1.4 RECENT DEVELOPMENTS 106
20.2 BAYER AG 108
20.2.1 COMPANY SNAPSHOT 108
20.2.2 REVENUE ANALYSIS 108
20.2.3 PRODUCT PORTFOLIO 109
20.2.4 RECENT DEVELOPMENTS 109
20.3 NOVARTIS AG 110
20.3.1 COMPANY SNAPSHOT 110
20.3.2 REVENUE ANALYSIS 110
20.3.3 PRODUCT PORTFOLIO 111
20.3.4 RECENT DEVELOPMENTS 111
20.4 LABORATORIOS BAGO S.A. 112
20.4.1 COMPANY SNAPSHOT 112
20.4.2 PRODUCT PORTFOLIO 112
20.4.3 RECENT DEVELOPMENTS 112
20.5 GLAXOSMITHKLINE PLC(2021) 113
20.5.1 COMPANY SNAPSHOT 113
20.5.2 REVENUE ANALYSIS 113
20.5.3 PRODUCT PORTFOLIO 114
20.5.4 RECENT DEVELOPMENT 114
20.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 115
20.6.1 COMPANY SNAPSHOT 115
20.6.2 REVENUE ANALYSIS 115
20.6.3 PRODUCT PORTFOLIO 116
20.6.4 RECENT DEVELOPMENTS 116
20.6.4.1 PARTNERSHIP 116
20.6.4.2 PRODUCT LAUNCH 117
20.7 NOVO NORDISK A/S 118
20.7.1 COMPANY SNAPSHOT 118
20.7.2 REVENUE ANALYSIS 118
20.7.3 PRODUCT PORTFOLIO 119
20.7.4 RECENT DEVELOPMENT 119
20.8 ABBVIE INC. 120
20.8.1 COMPANY SNAPSHOT 120
20.8.2 REVENUE ANALYSIS 120
20.8.3 PRODUCT PORTFOLIO 121
20.8.4 RECENT DEVELOPMENTS 121
20.9 ABBOTT 122
20.9.1 COMPANY SNAPSHOT 122
20.9.2 REVENUE ANALYSIS 122
20.9.3 PRODUCT PORTFOLIO 123
20.9.4 RECENT DEVELOPMENT 123
20.10 ACHE LABORATRIOS FARMACUTICOS S/A 124
20.10.1 COMPANY SNAPSHOT 124
20.10.2 REVENUE ANALYSIS 124
20.10.3 PRODUCT PORTFOLIO 125
20.10.4 RECENT DEVELOPMENTS 125
20.11 GADOR S.A. 126
20.11.1 COMPANY SNAPSHOT 126
20.11.2 PRODUCT PORTFOLIO 126
20.11.3 RECENT DEVELOPMENTS 126
20.12 LABORATORIOS BERNABO S.A. 127
20.12.1 COMPANY SNAPSHOT 127
20.12.2 PRODUCT PORTFOLIO 127
20.12.3 RECENT DEVELOPMENTS 127
20.13 LABORATORIO ELEA PHOENIX S.A. 128
20.13.1 COMPANY SNAPSHOT 128
20.13.2 PRODUCT PORTFOLIO 128
20.13.3 RECENT DEVELOPMENT 128
20.13.3.1 PRODUCT LAUNCH 128
20.14 QUIMICA MONTPELLIER S.A. 129
20.14.1 COMPANY SNAPSHOT 129
20.14.2 PRODUCT PORTFOLIO 129
20.14.3 RECENT DEVELOPMENTS 129
20.15 ROEMMERS SAICF 130
20.15.1 COMPANY SNAPSHOT 130
20.15.2 PRODUCT PORTFOLIO 130
20.15.3 RECENT DEVELOPMENTS 130
20.16 TEMIS LOSLATO 131
20.16.1 COMPANY SNAPSHOT 131
20.16.2 PRODUCT PORTFOLIO 131
20.16.3 RECENT DEVELOPMENTS 131
21 QUESTIONNAIRE 132
22 RELATED REPORTS 136
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
